4 protocol(s) meet the specified criteria
Disease Site: Other Urinary
Protocol No.TitleStatus
ASG-22CE-13-2A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects with Metastatic Urothelial Cancer and Other Malignant Solid Tumors that Express Nectin-4Open
ETCTN9767-CIRBAn Open Label, Multicenter, Single arm Phase II study to evaluate the Activity and Tolerability of the novel mTOR Inhibitor, MLN0128 (TAK-228), in patients with Locally Advanced or Metastatic Transitional Cell Carcinoma of the urothelial tract whose tumors harbor a TSC1 and/or a TSC2 mutation.Open
LCCC1734Adaptation of the Parenting Concerns Questionnaire for Patients with IllnessOpen
PCRC-14-07Caregiver-­‐guided pain management training in palliative careOpen